SCHEMBL6792990

SCHEMBL6792990

CCOC(=O)c1c2ccc3cc(OC)c(Br)cc3c2nn1CCCNC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SUV39H2 Q9H5I1 2/20 0.41
STING1 Q86WV6 3/20 0.40
DYRK1A Q13627 1/20 0.40
DRD2 P14416 4/20 0.39
BRD4 O60885 8/20 0.39
ALDH1A1 P00352 1/20 0.36
PDPK1 O15530 1/20 0.36
CCNB2 O95067 1/20 0.36
PRKCB P05771 1/20 0.36
CDK1 P06493 1/20 0.36
LYN P07948 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
GSK3B P49841 1/20 0.36
RPS6KA3 P51812 1/20 0.36
CCNA1 P78396 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6791887 0.90 SUV39H2 (0.42) SUV39H2STING1DYRK1ADRD2BRD4
SCHEMBL6792474 0.77 BRD4 (0.38) DYRK1ADRD2BRD4ALDH1A1PDPK1
SCHEMBL6787540 0.77 DRD2 (0.39) SUV39H2STING1DYRK1ADRD2BRD4
SCHEMBL6793931 0.76 DYRK1A (0.50) DYRK1ADRD2BRD4
SCHEMBL6793960 0.74 BRD4 (0.38) DYRK1ADRD2BRD4ALDH1A1PDPK1
SCHEMBL6791840 0.73 DYRK1A (0.51) DYRK1ADRD2BRD4
SCHEMBL6788076 0.72 AKR1C3 (0.37) SUV39H2DRD2BRD4ALDH1A1
SCHEMBL6786821 0.71 SUV39H2 (0.39) SUV39H2STING1DRD2BRD4ALDH1A1
SCHEMBL10218688 0.71 PIM1 (0.40) ALDH1A1
SCHEMBL6791673 0.70 DYRK1A (0.51) DYRK1ADRD2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 MKNK2, MAPKAPK2, MAP3K2 SUV39H2 3165/4885STING1 4141/4885DYRK1A 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.